This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Zosano Pharma Dirección

Dirección controles de criterios 2/4

Información clave

Steven Lo

Chief Executive Officer (CEO)

US$2.0m

Compensación total

Porcentaje del salario del CEO	26.2%
Permanencia del CEO	3.1yrs
Participación del CEO	0.06%
Permanencia media de la dirección	3.1yrs
Promedio de permanencia en la Junta Directiva	3.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Steven Lo en comparación con los beneficios de Zosano Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$2m	US$533k	-US$30m
Sep 30 2021	n/a	n/a	-US$31m
Jun 30 2021	n/a	n/a	-US$31m
Mar 31 2021	n/a	n/a	-US$33m
Dec 31 2020	US$1m	US$526k	-US$33m
Sep 30 2020	n/a	n/a	-US$34m
Jun 30 2020	n/a	n/a	-US$35m
Mar 31 2020	n/a	n/a	-US$37m
Dec 31 2019	US$875k	US$106k	-US$38m

Compensación vs. Mercado: Steven's total compensation ($USD2.03M) is above average for companies of similar size in the German market ($USD437.65K).

Compensación vs. Ingresos: Steven's compensation has increased whilst the company is unprofitable.

CEO

Steven Lo (55 yo)

3.1yrs

Permanencia

US$2,032,101

Compensación

Mr. Steven Lo has been Director at Zosano Pharma Corporation since October 2019 and serves as its President and Chief Executive Officer since October 21, 2019 and has been its Senior Vice President of Oper...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Steven Lo	Senior VP of Operations	3.1yrs	US$2.03m	0.055% $ 7.0
Christine Matthews	Chief Financial Officer	2.8yrs	US$675.66k	0.012% $ 1.5
Lu Liu	Vice President of Technical Operations	3.8yrs	sin datos	sin datos
Jeffrey Quillen	Secretary	no data	sin datos	sin datos

3.1yrs

Permanencia media

Equipo directivo experimentado: 0ZP's management team is considered experienced (3.1 years average tenure).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Steven Lo	Senior VP of Operations	3.1yrs	US$2.03m	0.055% $ 7.0
Kenneth Greathouse	Lead Independent Director	5.1yrs	US$97.84k	0.017% $ 2.1
Linda Grais	Independent Director	3.8yrs	US$96.98k	0.0044% $ 0.6
Kathy McGee	Independent Director	1.5yrs	US$89.00k	0% $ 0
Elaine Yang	Independent Director	less than a year	US$46.92k	sin datos

3.1yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: 0ZP's board of directors are considered experienced (3.1 years average tenure).

This company is no longer active

Zosano Pharma Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Joseph “Jay” P. Hagan Resigns as Director of the Board of Directors of Zosano Pharma Corporation

Steven A. Elms Tenders His Resignation as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Announces John Walker, Chairman of the Board of Directors to Retire from the Board

Recent updates

Emergex USA Corporation completed the acquisition of Substantially all assets of Zosano Pharma Corporation for $1 million.

Emergex USA Corp. agreed to acquire Substantially all assets of Zosano Pharma Corporation (OTCPK:ZSAN.Q) for $1.3 million.

Motion for Case Conversion Filed for Zosano Pharma Corporation

Motion for Asset Sale Filed by Zosano Pharma Corporation

Zosano Pharma Corporation to Delist from Nasdaq

Zosano Pharma Corporation Filed for Bankruptcy

First quarter 2022 earnings released: US$7.87 loss per share (vs US$2.73 loss in 1Q 2021)

Joseph “Jay” P. Hagan Resigns as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Reports Impairment Charges for the First Quarter Ended March 31, 2022

Steven A. Elms Tenders His Resignation as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Receives a Response Letter from the U.S. Food and Drug Administration with Regard to the Company’s January 18, 2022 Resubmission of the 505(b)(2) New Drug Application for M207

Zosano Pharma Corporation has completed a Composite Units Offering in the amount of $15.375 million.

Zosano Pharma Corporation has completed a Composite Units Offering.

Zosano Pharma Corporation Resubmits its M207 (Zolmitriptan Transdermal Microneedle System) 505(B)(2) New Drug Application to the U.S. Food and Drug Administration

Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of A Trivalent Influenza Vaccine Formulated on Its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine At A Higher Dose

Zosano Pharma Corporation Announces Publication of Clinical Data Regarding the Long-Term Use of Qtrypta for the Treatment of Acute Migraine in the Journal of Headache and Pain

Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA

Revenue in line with expectations

Zosano Pharma Corporation Announces John Walker, Chairman of the Board of Directors to Retire from the Board

Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA

New 90-day high: €1.26

Zosano Pharma Corporation Announces NDA Resubmission Plans Following Type A Meeting with FDA

New 90-day high: €0.90

New 90-day high: €0.64

Zosano Pharma Requests Type A Meeting with the Fda to Review Resubmission Plans for Qtrypta™ New Drug Application

Bragar Eagel & Squire, P.C. Reminds Investors of Class Action Lawsuit Filed Against Zosano Pharma Corporation

Pomerantz LLP Reminds Shareholders with Losses on Their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline

New 90-day low: €0.21

Rosen Announces Filing of Securities Class Action Lawsuit Against Zosano Pharma Corporation

New 90-day low: €0.54

New 90-day low: €0.64

Zosano Pharma Corporation Receives Discipline Review Letter from the U.S. Food and Drug Administration in Connection with the Qtrypta

Zosano Pharma Corporation has completed a Follow-on Equity Offering in the amount of $20.782018 million.

New 90-day high - €1.11

Zosano Pharma Corporation(NasdaqCM:ZSAN) dropped from Russell Microcap Growth Index

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad